Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & Events > News
In draft guidance published today, NICE recommends that anyone with type 1 diabetes who is pregnant or planning a pregnancy should be offered pregnancy-specific HCL technology.
The Steve Morgan Foundation has donated £280,000 to Breakthrough T1D and DigiBete to expand Coping with Diabetes online tool.
On Friday 15 May, Breakthrough T1D appeared on Piccadilly Lights alongside a new short film for EE72 featuring Kate Moss, captured by Nick Knight.
We are very sorry to share the news that Colin Brumpton, Entrepreneur, Business Consultant and a long‑standing supporter of Breakthrough T1D, passed away on 14 April.
Discussing the main themes from this year's Advanced Technologies & Treatments for Diabetes conference – early detection, cellular cures and disease-modifying therapies.
These lab-engineered cells have been able to evade the immune system and produce insulin for 14 months without the need for immunosuppression.
You may have seen headlines or social media posts about a new drug called tegoprubart, with some suggesting it could help people with type 1 diabetes (T1D) stop taking insulin.
We're delighted to announce that James Norton will be taking on the 2026 London Marathon for Team Breakthrough T1D.
Researchers funded by Breakthrough T1D in America have used small, electrical implant systems in lab-grown, insulin-producing cells.
A series of T1DE pilot schemes commissioned by NHS England are at risk of closure due to lack of funding.
The report calls for urgent action to close these gaps and protect vulnerable people from avoidable harm.
Breakthrough T1D is supporting a major new call to action urging Government and the sport and physical activity sector to remove barriers faced by people living with diabetes.
New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.
We're delighted to announce a £350,000 donation from the Bukhman Foundation to support our Community Engagement programme.
A major UK study has shown that screening children for type 1 diabetes (T1D) can identify the condition in its earliest stages, before symptoms appear, offering families time, choices, and hope.
The European Commission has approved Teizeild, the European brand name for the immunotherapy teplizumab, for use in people with stage 2 type 1 diabetes (T1D). This marks an important step forward in efforts to delay the progression of the condition.
Highlights from an extraordinary year in type 1 diabetes (T1D) research, treatment, advocacy and policy.
Breakthrough T1D has been made aware of a product update issued by Abbott for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors. Some sensors have been providing incorrect low glucose readings.
The Bukhman Foundation has donated the money to establish the Bukhman Centre for Research Excellence in Type 1 Diabetes.
These are the takeaways that matter most to our community from EASD, Europe’s biggest diabetes conference.
INNODIA has announced positive results from its clinical trial MELD-ATG at the EASD conference in Vienna this year.
Lyla died from diabetic ketoacidosis (DKA), a life-threatening complication that can occur when type 1 diabetes goes undiagnosed.
A new research paper has presented data that shows people breastfeeding with type 1 diabetes (T1D) need not let higher blood glucose levels stop them from breastfeeding their infants
NHS England has confirmed that some machines used to diagnose and monitor diabetes have produced inaccurate results, affecting people being assessed for type 2 diabetes.
We’re pleased to announce that we are launching a new initiative to raise awareness of the importance of early detection in type 1 diabetes (T1D), with support from Sanofi.
In a landmark moment, the MHRA has licensed the use of teplizumab in the UK, the first-ever disease-modifying therapy for T1D.
Steve Bates OBE, David Bruce and Dean Sowman will join our Board of Directors in October 2025.
In the study, nearly two thirds of young people diagnosed with type 1 diabetes (T1D) did not have the typical identifiers of the condition.
We've partnered with Barbie to create the world’s first Barbie doll with type 1 diabetes (T1D).
A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1.
We’re aware of growing concern around insulin supply in the UK, and we want to reassure our community that this is not a general insulin shortage. There is no need to change the type of insulin you use.
New data from Sana Biotechnology, in collaboration with Uppsala University Hospital in Sweden, shows that six months post-transplant, one person with type 1 diabetes (T1D) is successfully producing insulin and does not require immunosuppression.
US-based company Vertex has published promising figures from their cell therapy trial, showing advancements in stem cell research.
If you use the Dexcom G6 app on your Android smartphone, the newest Android 16 operating system may disrupt how the app functions.
We're calling for urgent reform as new report reveals older people with T1D are systematically failed by health and social care services.
Our CEO received the MBE in recognition of her exceptional services to people with type 1 diabetes (T1D).
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
